XTL BIOPHARMACEUTICALS LTD
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
About Xtl Biopharmaceuticals
Pharmaceutical Preparations, SIC 2834
XTL Biopharmaceuticals Ltd. is a biopharmaceutical company engaged in developing and commercializing therapeutic products. Through its operating entities, including its acquisitions of The Social Proxy and Psyga Bio Ltd., the company focuses on advancing drug development programs, such as early-stage psychedelic compounds and therapeutics. Its activities center on research and clinical development efforts, which rely on partnerships with contract research organizations and clinical trial sites. The company seeks to provide its pharmaceutical and healthcare solutions to patients and customers in target therapeutic markets.
The company maintains its corporate headquarters and principal executive offices in Herzliya, Israel. Its corporate footprint and clinical development activities are supported by executive leadership along with personnel across its operating subsidiaries in Israel. The organization coordinates its international business development, regulatory compliance, and clinical research across global pharmaceutical markets through third-party trial sites and partner networks.
Summary of the business section of Xtl Biopharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- XTL BIOPHARMACEUTICALS LTD
- Headquarters
- New York, NY
- Address
- Xtl Biopharmaceuticals Ltd, C/O Alston & Bird Llp, 90 Park Avenue 10016
- Phone
- 972 9 955 7080
- Employees
- 3, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- L3
- Auditor
- Barzily and Co. CPAs, Jerusalem, Israel
Stock & identifiers
- Ticker
- XTLB
- Exchange
- Nasdaq
- Shares outstanding
- 946M, Dec 31, 2025
- Filer category
- Non-accelerated filer
- Stock splits
- 1-for-4 reverse, Mar 25, 2026; 1-for-5 reverse, Feb 10, 2017; 1-for-10 reverse, Oct 4, 2012
- SEC CIK
- 1023549
- CUSIP
- 98386D406
- ISIN
- US98386D4060
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Fain Osnat Hillel | Director | – |
Employees
Headcount reported in annual reports
“Our subsidiaries have 3 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Apr 30, 2026 | Late filing | Notification of late filing |
| Jul 11, 2013 | Listing | Registration of securities on an exchange (Form 8-A) |
| Jul 10, 2009 | Delisting | Notice of delisting from exchange (Form 25) |